Professor Michel Michaelides
I would like to welcome you to my website and share with you my commitment to providing expert consultation and compassionate care to all patients and their families.
Throughout my years of work and experience and providing care for thousands of patients, I shaped my own philosophy which is built around the patient themselves as a vital part of the treatment journey rather than a one-way communication from the doctor side. My approach includes being family oriented and allows my patients and their families to have the opportunity to communicate with me freely and fully, so I can help them with innovative and personalized care and treatment options.
I place the utmost importance in helping patients feel comfortable and confident in the treatments and advice I provide, always upholding my personal and professional values of Compassion, Respect, and Excellence.
I welcome your comments and questions, so please feel free to communicate with me on my contact page here.
Prof. Michel Michaelides
Professor Michel Michaelides is a Consultant Ophthalmologist at Moorfields Eye Hospital in the departments of Medical Retina, Inherited Eye Disease and Paediatric Ophthalmology; and is a Professor of Ophthalmology at the UCL Institute of Ophthalmology.
His clinical and research interests include diabetic eye disease, age-related macular degeneration and inherited eye disease in adults and children; with over 300 peer-reviewed publications and 30 co-authored book chapters. He is actively involved in retinal clinical trials investigating novel and established therapies, being a principal investigator in 10 on-going clinical trials.
Furthermore, Professor Michaelides’s training has included a Medical Retina and Genetics clinical fellowship at Moorfields Eye Hospital, London, UK (2008-2009), and a combined Ophthalmic Genetics and Paediatric Ophthalmology clinical and research fellowship at Casey Eye Institute, Oregon Health and Science University, Portland, Oregon, USA (2009-2010).
He is also the recipient of a Career Development Award (5 years) from the Foundation Fighting Blindness (USA) – an award that is rarely given to non-US applicants, and also the Department of Health/HEFCE ‘New Blood’ Clinical Senior Lectureship Award (5 years); and has gained membership of the highly prestigious Macula Society and Retina Society in the USA.
Throughout the period of (2002-2004) he has undertaken a period of dedicated research with his doctoral thesis entitled: “Cone and Central Receptor Dystrophies – A Clinical and Molecular Genetic Investigation”.
He is acknowledged as a world authority and key opinion leader in inherited eye disease in both adults and children; with over 300 peer-reviewed publications and 30 co-authored book chapters. He has more than 400 publications since 2010; Google Scholar h-index of 68, i10-index of 270, with 20000 citations in total.
Furthermore, he has established both national (>60 co-authors) and international collaborations, including with Professors Joe Carroll and Alfredo Dubra (USA) who are world leaders in Adaptive Optics imaging and Professor Richard Weleber (USA) who is a leading developer of advanced visual field analysis.
He has a rich research portfolio which incorporates 12 on-going ethically approved studies, including multi-centre international natural history studies for Stargardt disease and USH2A-retinopathy, and he is also actively involved in retinal clinical trials investigating novel and established therapies, being a principal investigator in 10 on-going clinical trials, including gene therapy and the world’s first ocular stem cell therapy trial.
Professor Michaelides has been awarded funding from multiple sources including the National Institutes of Health-National Eye Institute (USA), Medical Research Council, National Institute for Health Research (NIHR), NIHR Rare Diseases Translational Research Collaboration, Wellcome Trust, Foundation Fighting Blindness (USA), Retina UK (UK), Fight For Sight (UK), Macular Society (UK), Bayer Healthcare, Moorfields Special Trustees, and Moorfields Eye Charity – totaling over £12,000,000.
Furthermore, Professor Michel Michaelides has made outstanding contributions to the fields of ophthalmology and visual science. His research has a strong translational focus with the aim of developing novel therapies for retinal diseases.
He has been a central figure in developing a strong collaborative team investigating retinal diseases at University College London (UCL) and Moorfields Eye Hospital over the last 20 years; providing key clinical leadership. His strength has been to identify key advances in basic science and then incorporate these into clinical research. This approach is highlighted by the development of high-resolution quantitative retinal imaging of individual photoreceptors in vivo through an adaptive optics scanning laser ophthalmoscope – the only one of its kind outside of the USA. This and other deep phenotyping of retinal diseases has greatly improved understanding of disease mechanisms and allowed the development of novel outcomes for clinical trials. He is a key member of a team developing gene and stem cell therapy at UCL, providing the clinical expertise and leadership. This has culminated in him being a founding member of a UCL gene therapy spin-out company, which was acquired by MeiraGTx, where he is Head of Clinical Ophthalmology and is now in partnership with Johnson & Johnson to develop a pipeline of gene therapies for inherited retinal diseases, age-related macular degeneration, and diabetic eye disease.
Professor Michaelides is a strong advocate for patients with retinal disease and has played a key role in improving the quality, depth and breadth of scientific, medical and research information available on the websites of several national and international patient support groups and charities.
I was always deeply intrigued by the human eye and fascinated at how complex it is. This fascination created a desire for me wanting to study and work in the field of ophthalmology.
Professor Michel Michaelides
Your message has been sent. We will get back to you.
